Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing

Xenon Pharmaceuticals Inc.

2022-FY EPS reported -$2.06 revenue$9,434,000

Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.
Revenue $9.4M for FY2022 vs $18.4M in 2021; no Q4 revenue.
Cash and marketable securities $720.8M as of Dec 31, 2022; sufficient into 2026.
XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) enrolling; topline MDD data expected Q3 2023.
Neurocrine partner Phase 2 FOS data expected H2 2023; XEN496 Phase 3 EPIK completion expected 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenon Pharmaceuticals Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 1, 2023, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.